11 Apr 2025

Permira Appoints George McMillan as Senior Adviser

“George’s extensive experience, especially in pharma services, is extremely valuable for our global healthcare portfolio and healthcare strategy going forward. George has already proven to be a highly valuable partner to date, and we look forward to welcoming George to Permira as a Senior Adviser.”
Laura O’Donnell
Healthcare Managing Director at Permira
Share to Linkedin

London, 11 April 2025 – Permira, the global investment firm, today announces the appointment of seasoned healthcare executive, George McMillan, as a Senior Adviser to its global Healthcare team.

George brings over 25 years of experience in the healthcare industry to Permira, with a successful track record in executive leadership roles. He has a deep knowledge of the clinical research industry with over a decade-long career, most recently as Chief Commercial Officer at ICON, a leading clinical research organisation providing outsourced clinical development and commercialisation services to healthcare organisations globally. Prior to ICON, George was the Chief Financial Officer of PharmaNet Development Group, which was acquired by Inventiv.

Prior to joining the clinical research industry in 2010, George held senior operations and finance positions in a series of international businesses focused on technology-related professional services. He served as CEO of Palladium Group, a leader in corporate performance management software and consulting; CFO and CEO of CMGI, a leading internet holding company; and CFO/COO of Renaissance Solutions, a strategic consulting and technology services company.

George's extensive experience and expertise in the healthcare sector will be highly valuable to Permira's Healthcare team. In his role, George will partner with investment teams to identify new opportunities globally and help portfolio company management teams drive value creation initiatives. 

Permira is an active global investor in the healthcare sector, having deployed over €5 billion to partner with approximately 20 companies globally. Current investments from the Permira funds in the sector include PharmaCord, Ergomed, Kedrion Biopharma, Neuraxpharm, Cambrex, Quotient Sciences, I-MED and Corin.

Peter Michel, Healthcare Managing Director at Permira, said: “It’s been a pleasure getting to know George over the past two years. He brings over two decades of experience within pharma services; his deep knowledge of the clinical research space and healthcare service platforms, along with his network in the pharmaceuticals industry, are invaluable to our healthcare franchise and we are excited to welcome him to the team.”

Laura O’Donnell, Healthcare Managing Director at Permira, added: “George’s extensive experience, especially in pharma services, is extremely valuable for our global healthcare portfolio and healthcare strategy going forward. George has already proven to be a highly valuable partner to date, and we look forward to welcoming George to Permira as a Senior Adviser.”

George McMillan, Senior Adviser at Permira, said: "I am thrilled to be joining Permira, a firm known for its deep understanding of healthcare, investments across healthcare services and commitment to long-term value creation. I look forward to leveraging my experience to support the healthcare team and help drive growth and innovation for Permira's portfolio companies and stakeholders."